ArticleThe World Allergy Organization journal2025

Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab.

Koremasa Hayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.